Yancy Clyde W
Departments of Medicine and Cardiology, Heart Failure/Transplantation Services, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rev Cardiovasc Med. 2002;3 Suppl 3:S27-35.
Outcomes for heart failure have improved considerably with the implementation of neurohormonal antagonism that includes angiotensin-converting enzyme inhibitors and beta-blockers. Despite the robust benefit of beta-blockers for heart failure, it is not clear that the benefit can be extended to all patient groups. Special clinical consideration thus needs to be given to the elderly, women, and African Americans. A retrospective review of available data suggests that despite differences in the natural history of heart failure for these groups, significant benefit can still be expected from the use of beta-blockers for heart failure. Future trials will address these groups in a prospective manner.
随着包括血管紧张素转换酶抑制剂和β受体阻滞剂在内的神经激素拮抗剂的应用，心力衰竭的治疗效果有了显著改善。尽管β受体阻滞剂对心力衰竭有显著益处，但尚不清楚这种益处是否能扩展到所有患者群体。因此，对于老年人、女性和非裔美国人需要给予特殊的临床考虑。对现有数据的回顾性分析表明，尽管这些群体心力衰竭的自然病史有所不同，但使用β受体阻滞剂治疗心力衰竭仍有望获得显著益处。未来的试验将以前瞻性的方式针对这些群体展开研究。
